跳至主要内容
临床试验/NCT03391752
NCT03391752已完成不适用

More-2-Eat Phase 2: Spread/Scaling up Improved Nutrition Care to Detect and Treat Hospital Malnutrition.

University of Waterloo9 个研究点 分布在 1 个国家目标入组 5,158 人开始时间: 2018年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
5,158
试验地点
9
主要终点
success with implementation

研究概览

简要总结

More-2-Eat Phase 2 provides the opportunity to extend the implementation of the Integrated Nutrition Pathway to a total of 10 hospitals and more than 20 medical/surgical units. Building on the success of More-2-Eat Phase 1, key components of this implementation study will be a registry for self-managed data entry and reports and a community of practice to support implementation of nutrition screening at admission to hospital, subjective global assessment to diagnose and triage patients to care pathways and medication pass of a small amount of nutrient dense oral nutritional supplement. Success with implementation and impact on key patient outcomes will be determined.

详细描述

Malnutrition in hospital patients is a growing problem, with 20-45% of patients already malnourished at admission. As 70% of malnourished patients are also frail, early detection and treatment of malnutrition is one way to improve the outcomes of frail older adults. To improve the detection and treatment of these conditions, the PI developed the Integrated Nutrition Pathway for Acute Care (INPAC) that guides hospital staff on when to conduct key nutrition care activities to improve outcomes (e.g. screening at admission).

In More-2-Eat (April 2015-March 2017), 5 Canadian hospital units in 4 provinces received funding to implement INPAC. Each hospital, with support from a research team had 1 year to implement INPAC. All 5 hospitals were successful in improving detection and treatment of malnutrition, and started to screen for frailty. Clinical care was transformed in the study units; for example all sites progressed from low baseline or no screening at admission to a rate of 75%. Findings also demonstrate improvement in clinical outcomes such as a shorter length of stay. An online INPAC Implementation Toolkit was developed to promote mobilization of this knowledge. What is not known is whether or not the results can be replicated under normal circumstances (i.e., no external funding for implementation at a hospital site).

To sustain and expand on this success, a Phase 2 knowledge translation project is proposed that will involve the five original Phase 1 sites and five further hospitals as Phase 2 sites. The goal of the second phase is to see if Phase 1 sites can spread success to other units within their hospitals and if Phase 2 sites can achieve similar results across a broader group of patients.

The end product will be a sustainable model including a community of practice supported by our partner the Canadian Malnutrition Task Force, and a self-serve registry that allows sites to collect and report data to change their practice. Investigators will also confirm capacity of INPAC activities to improve clinical outcomes across diverse settings. This knowledge translation and implementation study will demonstrate the potential to transform clinical nutrition care, benefiting all pre-frail and frail older adults.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient on the study unit

排除标准

  • patients not on the study unit

结局指标

主要结局

success with implementation

时间窗: 19 months

rates of screening, diagnosis and treatment with medication pass per month of the study

次要结局

  • Adverse events while in hospital (fall, new infection etc.)(19 months)
  • Length of stay(19 months)
  • Readmission rate(19 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Heather Keller

Schlegel-University of Waterloo Research Chair, Nutrition & Aging

University of Waterloo

研究点 (9)

Loading locations...

相似试验

进行中(未招募)
1 期
Estudio abierto de extensión de fase 2 con conatumumab .A Phase 2 Open Label Extension Study of Conatumumab.diferentes tumores sólidos, incluyendo, entre otros, cáncer colorrectal (CCR), cáncer de pulmón de células no pequeñas (CPCNP), sarcoma de tejidos blandos (STB), linfoma no Hodgkin (LNH), cáncer de páncreas y cáncer de ovario. Different solid tumors, including, but not limited to, colorectal cancer (CRC), non small cell lung cancer(NSCLC), soft tissue sarcoma (STS), pancreatic cancer, and ovarian cancer and non-Hodgkins lymphoma(NHL).MedDRA version: 12.1Level: LLTClassification code 10007050Term: Cancer
EUCTR2010-022270-14-ESAmgen Inc12
进行中(未招募)
不适用
Estudio de extensión, fase 2b, abierto, multicéntrico, para evaluar la seguridad, tolerabilidad e inmunogenicidad de una dosis de refuerzo de la vacuna recombinante de Novartis contra el meningococo del grupo B administrada a los 12,18 ó 24 meses de edad a niños que con anterioridad hayan recibido una primera serie de tres dosis de la vacuna recombinante de Novartis contra el meningococo del grupo B en el estudio V72P12so de una cuarta dosis (dosis de refuerzo) de rMenB+OMV NZ para evaluar la seguridad, tolerabilidad e inmunogenicidad y explorar la persistencia de anticuerpos bactericidas a los 12, 18 y 24 meses de edad en la prevención de la meningitis y/o septicemia causada por N. meningitidis de tipo B. Se administrarán dos dosis de puesta al día de rMenB+OMV NZ a niños aún no inmunizados para generar datos para evaluar la seguridad e inmunogenicidad de un régimen de puesta al día de dos dosis.
EUCTR2009-011676-30-ESovartis Vaccines and Diagnostics S.r.l.1,900
招募中
不适用
Re-Source Phase II: Strengthening health resources among teachers.The intervention group are teachers who may have various health impairments, such as back pain or sleep disorders. These are compared with teachers who potentially have similar impairments but do not participate in the intervention in Bad Brückenau.
DRKS00026768Institut und Poliklinik für Arbeits-, Sozial- und Umweltmedizin der Friedrich-Alexander Universität Erlangen-Nürnberg70
招募中
2 期
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldDuchenne Muscular Dystrophy
NCT06769633Italfarmaco18
已完成
3 期
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1Meningococcal DiseaseMeningococcal Meningitis
NCT01717638Novartis Vaccines805